Nyxoah Reports Impressive Third Quarter Financials
Nyxoah, a prominent medical technology company specializing in innovative solutions for Obstructive Sleep Apnea (OSA), reported robust financial and operational results for the recent quarter. This period has been marked by a dynamic entry into the U.S. market, with their signature product, the Genio system, paving the way for substantial growth in revenue.
Major Highlights from the Financial Report
During the third quarter, Nyxoah made notable strides, including the first successful commercial implants in the U.S. market, generating initial revenue. This milestone was achieved with significant payer coverage, which greatly contributed to their financial results.
Revenue and Growth
In the third quarter of 2025, Nyxoah reported revenues of €2.0 million, reflecting a remarkable 56% increase compared to €1.3 million in the same period of the previous year. This growth demonstrates the increasing recognition and adoption of their innovative health solutions.
Reimbursement Achievements
Nyxoah successfully secured reimbursement from Medicare and several private payers, achieving a flawless 100% approval rate on prior authorization submissions from key insurers. This included notable approvals under the CPT code 64568, which further strengthened their financial outlook and paved the way for increased patient access to the Genio system.
Operational Advancements
The company's operational focus remained sharp, targeting high-volume centers for hypoglossal nerve stimulation. The Genio devices were first implanted at Townsend Memorial Health System, where the surgeon achieved five procedures in the opening week, indicating a promising start. Furthermore, medical personnel training has ramped up, with 111 surgeons trained on the Genio system as of October 31.
Strategic Development and Referrals
Nyxoah has been actively developing referral networks with sleep specialists, enhancing patient access to their treatment options. With 102 value analysis committee submissions completed and 35 approvals, their proactive approach is paying dividends. The company has also initiated 63 prior authorizations through the Genio Access Program, securing 21 approvals thus far.
Challenges and Responses
Despite substantial revenue growth, Nyxoah reported an operating loss of €24.4 million for the quarter, up from €15 million a year prior. This increase is primarily attributable to heightened research and development expenses and costs tied to scaling up the commercialization of the Genio system in the U.S. market.
Investment in Innovation
Nyxoah has notably increased its research and development expenditures, reaching €12.9 million this quarter compared to €7.9 million in the third quarter of 2024. This investment supports their ongoing commitment to advancing innovative treatments for OSA, particularly as they look to develop more comprehensive care strategies for their patients.
Update on Financial Position
Nyxoah's cash reserves stood at €22.5 million as of September 30, 2025, a decrease from €43.0 million at the end of the previous quarter. This shift poses a challenge, yet the favorable revenue growth from the recent U.S. market launch positions the company well for future success.
Looking Ahead: Nyxoah's Continued Efforts
As momentum builds in the U.S. market, Nyxoah remains focused on enhancing patient outcomes and expanding access to their Genio system. The company will host a conference call to discuss these results in further detail, inviting stakeholders to engage with their vision for the future of OSA treatment.
Frequently Asked Questions
What is the Genio system?
The Genio system is Nyxoah's leading product, providing a hypoglossal neurostimulation therapy designed to treat obstructive sleep apnea without invasive surgery.
How did Nyxoah perform financially in Q3 2025?
Nyxoah reported revenues of €2.0 million, marking a 56% increase year-over-year from €1.3 million in Q3 2024.
What reimbursement approvals did Nyxoah secure?
Nyxoah achieved reimbursement from Medicare and several private payers, with a 100% approval rate on prior authorization submissions this quarter.
What were the challenges faced by Nyxoah this quarter?
Nyxoah experienced an operating loss of €24.4 million for Q3, driven by increased R&D and commercialization costs associated with the Genio system.
What are Nyxoah's future plans?
Nyxoah plans to continue expanding its U.S. market presence while enhancing patient access and care through continued innovation and partnerships.
